Genocea finds new malaria biomarker

Genocea Profiles T cell Responses to Identify Antigens Associated with Malaria Episodes Findings reveal evidence of malaria in immune system years after clinical episodes November 5, 2014 Genocea Biosciences, Inc., a company developing T cell-directed vaccines and immunotherapies, today presented study results identifying a cluster of antigens that may be a biomarker of disease. The findings, generated using Genocea’s proprietary …

Genocea Announces Positive Top-Line 12-Month Follow-up Data from Phase 1/2a Clinical Trial for HSV-2 Immunotherapy GEN-003

Full Data in Oral Presentation at Major Infectious Disease Medical Meeting in October 2014 June 1, 2014 Genocea Biosciences, Inc., a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, today announced positive top-line 12-month follow-up data from a Phase 1/2a study of GEN-003, the Company’s immunotherapy candidate against herpes simplex virus type 2 (HSV-2). At 12 months after the …

Genocea Biosciences Announces Collaboration to Characterize T Cell Responses to Cancer Antigens

March 3, 2014 Genocea Biosciences, Inc., a company pioneering novel T cell vaccines and immunotherapies, today announced a joint research collaboration with Dana-Farber Cancer Institute and Harvard Medical School to characterize anti-tumor T cell responses in melanoma patients. This collaboration extends the use of the company’s proprietary ATLAS™ platform for the rapid discovery of T cell antigens to cancer immunotherapy approaches. “ATLAS™ has proven …

Published data supports innovative HSV-2 therapeutic vaccine GEN-003

Genocea Biosciences have announced the publication of preclinical trial results for their investigational therapeutic HSV-2 vaccine. The results, published in Journal of Virology, show that vaccination with GEN-003 and Isconova AB's Matrix-M adjuvant was capable of inducing antigen- and virus-specific immune responses. The vaccine improved outcomes in preclinical models of HSV-2 disease. GEN-003 showed a significant impact on viral shedding …